Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Malignant Ovarian Epithelial Tumor: early-phase trial registry

1 of 1 indexed Malignant Ovarian Epithelial Tumor trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Malignant Ovarian Epithelial Tumor: 1 US clinical trial tracked, 1 recruiting.

Malignant Ovarian Epithelial Tumor is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Ira Winer, running 1 of these trials.

Enrollment posture brief

Registry condition malignant-ovarian-epithelial-tumor

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Malignant Ovarian Epithe (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Malignant Ovarian Epithelial Tumor

Malignant Ovarian Epithelial Tumor lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Malignant Ovarian Epithelial Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Malignant Ovarian Epithelial Tumor is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Ira Winer 1 trials

Named interventions

Most-linked intervention names on Malignant Ovarian Epithelial Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Akt/ERK Inhibitor ONC201 Drug
1 trials
Questionnaire Administration Other
1 trials
Paclitaxel Drug
1 trials

US sites by state

Facility locations filed on Malignant Ovarian Epithelial Tumor trials. A trial with sites in several states counts in each.

Michigan 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Malignant Ovarian Epithelial Tumor page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Malignant Ovarian Epithelial Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Ira Winer sponsors the most Malignant Ovarian Epithelial Tumor trials on record, review their full trial history before evaluating a specific study. See Ira Winer's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Ovarian Epithelial Tumor condition card totals 1 registered trials; most-linked intervention Akt/ERK Inhibitor ONC201; top US site state Michigan. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.